Alliancebernstein L.P. Halozyme Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 3,408,341 shares of HALO stock, worth $145 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

3,408,341

Previous 3,549,075 3.97%

Holding current value

$145 Million

Previous $186 Million 4.93%

% of portfolio

0.07%

Previous 0.07%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $7.22 Million - $9.07 Million	-140,734 Reduced 3.97%	3,408,341 $195 Million
Q2 2024 Aug 14, 2024	SELL	$37.81 - $52.4 $4.43 Million - $6.14 Million	-117,249 Reduced 3.2%	3,549,075 $186 Million
Q1 2024 May 14, 2024	BUY	$33.68 - $41.95 $6.82 Million - $8.5 Million	202,630 Added 5.85%	3,666,324 $149 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $3.56 Million - $4.5 Million	106,918 Added 3.19%	3,463,694 $128 Million
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $92.4 Million - $112 Million	2,534,052 Added 308.01%	3,356,776 $128 Million
Q2 2023 Aug 15, 2023	BUY	$30.28 - $38.74 $234,821 - $300,428	7,755 Added 0.95%	822,724 $29.7 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $96,115 - $162,922	-2,925 Reduced 0.36%	814,969 $31.1 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $3.77 Million - $5.6 Million	-94,205 Reduced 10.33%	817,894 $46.5 Million
Q3 2022 Nov 15, 2022	SELL	$38.53 - $51.78 $2.78 Million - $3.74 Million	-72,135 Reduced 7.33%	912,099 $36.1 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $685,858 - $886,932	18,363 Added 1.9%	984,234 $43.3 Million
Q1 2022 May 13, 2022	BUY	$31.97 - $41.06 $1.13 Million - $1.45 Million	35,420 Added 3.81%	965,871 $38.5 Million
Q4 2021 Feb 14, 2022	BUY	$31.82 - $40.75 $4.53 Million - $5.8 Million	142,393 Added 18.07%	930,451 $37.4 Million
Q3 2021 Nov 10, 2021	BUY	$38.47 - $46.42 $9.17 Million - $11.1 Million	238,456 Added 43.39%	788,058 $32.1 Million
Q2 2021 Jul 30, 2021	BUY	$38.84 - $51.31 $6.44 Million - $8.51 Million	165,870 Added 43.23%	549,602 $25 Million
Q1 2021 May 06, 2021	SELL	$39.51 - $51.45 $2.2 Million - $2.86 Million	-55,685 Reduced 12.67%	383,732 $16 Million
Q4 2020 Feb 08, 2021	BUY	$25.81 - $43.62 $4.06 Million - $6.86 Million	157,341 Added 55.78%	439,417 $18.8 Million
Q3 2020 Nov 12, 2020	SELL	$25.74 - $29.63 $1.29 Million - $1.48 Million	-50,084 Reduced 15.08%	282,076 $7.41 Million
Q2 2020 Aug 13, 2020	BUY	$16.25 - $26.81 $234,000 - $386,064	14,400 Added 4.53%	332,160 $8.91 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $173,750 - $272,875	-12,500 Reduced 3.78%	317,760 $5.72 Million
Q4 2019 Feb 18, 2020	SELL	$14.93 - $19.53 $116,454 - $152,334	-7,800 Reduced 2.31%	330,260 $5.86 Million
Q2 2019 Aug 14, 2019	BUY	$14.75 - $17.26 $307,537 - $359,871	20,850 Added 6.57%	338,060 $5.81 Million
Q1 2019 May 14, 2019	BUY	$13.94 - $17.58 $22,304 - $28,127	1,600 Added 0.51%	317,210 $5.11 Million
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $357,057 - $499,826	26,786 Added 9.27%	315,610 $4.62 Million
Q3 2018 Nov 08, 2018	SELL	$16.68 - $18.41 $72,724 - $80,267	-4,360 Reduced 1.49%	288,824 $5.25 Million
Q2 2018 Aug 13, 2018	BUY	$16.87 - $20.3 $330,652 - $397,880	19,600 Added 7.16%	293,184 $4.95 Million
Q1 2018 May 14, 2018	BUY	$17.06 - $21.2 $32,925 - $40,916	1,930 Added 0.71%	273,584 $5.36 Million
Q4 2017 Feb 13, 2018	BUY	$16.75 - $20.8 $1.59 Million - $1.98 Million	94,960 Added 53.74%	271,654 $5.5 Million
Q3 2017 Nov 13, 2017	BUY	$11.76 - $17.4 $2.08 Million - $3.07 Million	176,694	176,694 $3.07 Million

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $5.93B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Halozyme Therapeutics, Inc. Transaction History